Disopyramide Phosphate (Page 4 of 4)
Pediatric Dosage
Controlled clinical studies have not been conducted in pediatric patients; however, the following suggested dosage table is based on published clinical experience.
Total daily dosage should be divided and equal doses administered orally every 6 hours or at intervals according to individual patient needs. Disopyramide plasma levels and therapeutic response must be monitored closely. Patients should be hospitalized during the initial treatment period, and dose titration should start at the lower end of the ranges provided below.
Age (years) | Disopyramide (mg/kg body weight/day) |
---|---|
| |
Under 1 | 10 to 30 |
1 to 4 | 10 to 20 |
4 to 12 | 10 to 15 |
12 to 18 | 6 to 15 |
HOW SUPPLIED
Disopyramide phosphate is supplied in hard gelatin capsules containing either 100 mg or 150 mg of disopyramide base, present as the phosphate.
Disopyramide phosphate 100-mg capsules are white and orange, with markings SEARLE, 2752, NORPACE, and 100 MG.
NDC Number | Size |
---|---|
59762-0386-1 | bottle of 100 |
Disopyramide phosphate 150-mg capsules are brown and orange, with markings SEARLE, 2762, NORPACE, and 150 MG.
NDC Number | Size |
---|---|
59762-0400-1 | bottle of 100 |
Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F). [See USP Controlled Room Temperature.]
This product’s label may have been updated. For current full prescribing information, please visit www.greenstonellc.com.
Rx only
LAB-1270-1.0
Revised March 2018
PRINCIPAL DISPLAY PANEL — 100 mg Capsule Bottle Label
NDC 59762-0386-1
100 Capsules
GREENSTONE® BRAND
disopyramide
phosphate
capsules USP
100 mg*
Rx only
PRINCIPAL DISPLAY PANEL — 150 mg Capsule Bottle Label
NDC 59762-0400-1
100 Capsules
GREENSTONE® BRAND
disopyramide
phosphate
capsules USP
150 mg*
Rx only
DISOPYRAMIDE PHOSPHATE disopyramide phosphate capsule, gelatin coated | ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
|
DISOPYRAMIDE PHOSPHATE disopyramide phosphate capsule, gelatin coated | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
|
Labeler — Greenstone LLC (825560733) |
Registrant — Pfizer Inc (113480771) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Viatris Pharmaceuticals LLC | 829084552 | ANALYSIS (59762-0386), ANALYSIS (59762-0400), MANUFACTURE (59762-0386), MANUFACTURE (59762-0400), PACK (59762-0386), PACK (59762-0400), LABEL (59762-0386), LABEL (59762-0400) |
Revised: 09/2023 Greenstone LLC
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.
https://medlibrary.org/lib/rx/meds/disopyramide-phosphate-3/page/4/